Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

诱导多能干细胞（iPSC）能再分化成特定的细胞类型、组织和器官，联合基因编辑技术使用，可用于探索疾病发生的机制、开发新型有效的药物和细胞 ...

诱导多能干细胞（iPSC）能再分化成特定的细胞类型、组织和器官，联合基因编辑技术使用，可用于探索疾病发生的机制、开发新型有效的药物和细胞治疗等。赛业生物iPSC体外技术服务平台，拥有成熟的重编程、基因编辑和体外分化技术，同时结合一站式表型 ...

五、针对下游应用优化关键PIVs 拟胚体（EB）的大小和密度（每毫升EB数）是iPSC聚集体分化为自然杀伤（NK）免疫细胞的关键工艺输入变量（PIVs）。虽然目前尚未确定从iPSC EBs生成NK细胞的最佳EB大小和密度，但这些PIVs可以通过调整生物反应器的搅拌速率（流体 ...

FATE uses its platform with iPSC technology that can create reprogrammed stem cells. In turn, these specially designed stem cells can produce all kinds of human cells, including T and NK cells.

Drug screening on iPSC-derived neurons could be implemented in two ways. First, the drug candidates could be tested in vivo on the iPSC-derived neurons generated from the patient who needs the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

该研究为进一步改造iPSC以获得具有增强功能的合成 ... 这项新的研究表明，这意味着nk细胞疗法可能能够批量生产，并为患者准备就绪，使之可以 ...

In North Korea, sudden financial improvements often trigger suspicion, especially in border regions where many rely on forbidden activities like smuggling FILE PHOTO: A border patrol checkpoint in ...

2025 年 1 月 13 日，庆应义塾大学医学院的研究人员在 Cell 子刊 Cell Reports Medicine 上发表了题为：A first-in-human clinical study of an allogenic iPSC-derived corneal endothelial cell substitute transplantation for bullous ...